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1. Introduction 
Cardiovascular diseases are the leading cause of morbidity and mortality in both dialysis 
dependent patients and those either waiting for or following up after renal transplantation. 
Concerns about the risk of contrast-induced acute kidney injury (CI-AKI) associated with 
coronary angiography in patients with stage 4 or 5 chronic kidney disease (CKD) have 
sometimes resulted in coronary angiography being delayed until after transplantation. 
Pretransplant cardiovascular disease is a well established risk factor for post transplant 
cardiovascular disease and cardiovascular mortality. In addition, post transplant 
dyslipidemia, 1-3 hypertension, 4-7 allograft dysfunction, delayed or slow graft function8 and 
post transplant erythrocytosis 9, 10 are some of the more specific factors that increase 
cardiovascular risk in renal transplant recipients as compared to the general population. 
Prompt diagnosis and treatment of cardiovascular disease in CKD and end stage renal 
disease population prior to transplant is aimed to reduce cardiovascular morbidity and 
mortality in the perioperative period and beyond. Several studies have demonstrated that 
left ventricular function and hypertrophy improve after renal transplantation. Ferreira et al 
prospectively studied 24 patients with end stage renal disease and demonstrated a 
significant decrease in hypertension, reduction in left ventricular hypertrophy and dilation, 
and improvement in systolic function after successful renal transplantation.11 Wali et al 
followed up 103 renal patients with left ventricular ejection fraction less than 40% with 
radionuclide ventriculography and renal transplantation and found the mean left 
ventricular ejection fraction increased from 31.6% to 52.2% at 12 months after 
transplantation. A longer pre-transplantation interval decreased the likelihood of 
normalization of ejection fraction. New York Heart Association functional status improved 
significantly concordant with an improvement of ejection fraction. These studies indicate 
that renal transplantation should not be withheld for patients with severe cardiac 
dysfunction as both left ventricular function and survival are expected to improve with 
renal transplantation.12 
This chapter will describe the approach to patients with CKD who are being considered for 
renal transplantation. Careful consideration to the background history, risk of 
cardiovascular disease, and risk of atherosclerotic events with the transplant operation will 
be discussed. The risks and benefits of coronary revascularization will be outlined in the 
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context of a patient with very little renal function remaining at the time of evaluation. 
Finally, we will summarize the major caveats for coronary angiography in patients who 
have received a kidney transplant and are being evaluated for new symptoms. 
2. Preoperative cardiovascular evaluation prior to renal transplantation 
Cardiovascular screening is recommended in certain groups of high risk CKD patients 
prior to transplantation.13 These include persons with diabetes, men over age 45 years, 
women over 55 years, previous history of ischemic heart disease, an abnormal 
electrocardiogram, left ventricular dysfunction, smoking history and duration of dialysis 
more than 2 years.14 Controversies exist regarding the ideal screening test for coronary 
artery disease among exercise stress test, dobutamine stress echocardiogram, and 
myocardial perfusion studies. Lentine et al in 2008 analyzed the United States Renal Data 
System on 27,786 eligible patients for renal transplantation and concluded that 46.3% of 
patients underwent cardiac evaluation prior to transplantation, of whom 9.5% required 
coronary revascularization. Among patients transplanted without cardiovascular 
evaluation, the three-year incidence of post transplant acute myocardial infarction was 3% 
in lower risk group and 10% in higher risk group.15   
All patients should be assessed for ischemic heart disease before renal transplantation. The 
minimum workup required includes a history, physical examination, electrocardiogram, 
and a chest radiograph.13 Assessment of functional status is critical. In general, if a patient 
can sustain a moderate or high work rate (> 5 metabolic equivalents of work) without 
symptoms, then there is a low risk of perioperative myocardial infarction or cardiovascular 
death. The pretest probability of coronary artery disease plays a major role in determination 
of cardiac testing. The Canadian society of transplantation recommends noninvasive testing 
for symptomatic patients or patients with prior history of coronary artery disease, as well as 
asymptomatic patients with diabetes mellitus  or  multiple risk factors for coronary artery 
disease.17 The choice of noninvasive testing has been a matter of debate with nuclear 
scintigraphy showing a high negative predictive value and performing well in diabetic 
patients.18-21 Marwick et al has shown that the sensitivity of dipyridamole thallium 
scintigraphy in patients with CKD is lower than that of controls.22 The speculated reasons 
for this observation are reduced coronary flow reserve, left ventricular hypertrophy and 
interstitial cardiac fibrosis. Results with stress echocardiography have been found to be 
comparable to nuclear imaging, 23, 24 and the expertise of technical and physician personnel 
often plays the major role in determining which test will be done at each institution. The 
Society further recommends coronary angiography be performed in patients with a positive 
noninvasive test or in very high risk patients irrespective of a noninvasive test. De Lima and 
colleagues have shown that coronary angiography is the best predictor of cardiac events in 
renal transplant candidates when compared to clinical risk stratification and non invasive 
testing.16 Some centers advocate angiography in most transplant candidates with diabetes, 
while others pursue cardiac catheterization only in candidates with positive screening 
examination.25 Low risk patients, asymptomatic patients with a negative noninvasive test 
result or noncritical disease on angiography on appropriate medical therapy, or who have 
undergone successful intervention can be considered eligible for transplantation without 
any further evaluation. Coronary angiography remains the gold standard for evaluation of 
coronary arteries among patients with positive screening tests or high risk of cardiovascular 
events. It is complicated by its invasive nature and the risk of contrast nephropathy and 
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cholesterol embolism which will be discussed below.14 The yield of coronary angiography in 
this population is high. De Lima et al in 2003 found that about 42% of patients in this group 
had significant coronary artery stenosis (more than 70% by visual estimation). Significant 
coronary artery stenosis was also the most significant predictor of cardiac events at 48 
months.16 A suggested approach to preoperative cardiovascular assessment and non 
invasive stress testing in CKD patients prior to renal transplantation is proposed by 
Karthikeyan et al in Figure 1.39 Abnormal results on non invasive stress tests such as 
coronary CT angiography and myocardial perfusion imaging often need invasive coronary 
angiography for diagnosis and possible intervention. This will lead to unnecessary delay, 
contrast and radiation exposure. So initial invasive coronary angiography is preferable in 
patients with multiple co-morbidities and risk factors and those with intermediate to high 
pre-test probability for non-invasive stress testing.  
 
 
Fig. 1. 
Adapted from Cardiology Review (2009); 5: page 183 
3. Risk and benefits of coronary angiography in transplant recipients 
The major risks of coronary angiography in renal transplant candidates are CI-AKI and 
cholesterol embolism which may hasten the progression to dialysis. In the general 
population, the risk of CI-AKI is 3.3 – 14.5%.26  Risk factors include reduced renal filtration 
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function, older age, diabetes, congestive heart failure and preprocedure myocardial 
infarction.27  Acute kidney injury requiring dialysis is rare but may occur in 0.44 to 0.77% of 
patients. This development is associated with a significant in hospital mortality rate of 35.7 
to 39%. The risk of CI-AKI is higher among pretransplant candidates because of their 
underlying advanced chronic kidney disease and  is estimated to be 4-50% with 8-26% 
eventually requiring dialysis at some point prior to transplantation.28 Gruberg et al reported 
that 4.9% of patients with baseline creatinine more that 1.8mg/dl required temporary 
dialysis after coronary angiography.29 Cholesterol embolism occurs from disruption of 
vascular endothelial plaques  resulting in release of cholesterol crystals into the blood 
stream. In severe forms, it may lead to localized inflammation and fibrosis most commonly 
seen in the skin, digits, kidney and eye. The reported incidence after coronary angiography 
is as high as 2% and manifests as persistent elevation of creatinine up to 3 weeks after the 
procedure.30 The relative contribution of subtle degrees of cholesterol embolism without 
peripheral signs to AKI is unknown. Further studies are warranted to assess the exact 
impact of this entity on pretransplant candidates undergoing coronary angiography and 
evaluate potential measures to reduce their incidence. 
4. Safety of coronary angiography in pretransplant candidates 
Contrast-induced AKI remains an important and potentially avoidable complication after 
coronary angiography and coronary and vascular interventions.40 A direct inverse 
relationship exists between a patient’s estimated glomerular filtration rate (eGFR) and their 
risk of contrast-induced AKI.41 In the setting of severely reduced renal filtration, the risk of 
sustained intrarenal vasoconstriction, tubular and peritubular stasis of contrast agents, 
cellular toxicity and permanent loss of functioning nephrons are greatly increased.42 Because 
coronary events are a major cause of perioperative risk and postoperative morbidity in 
patients considered for renal transplantation, coronary angiography is frequently performed 
prior to transplantation, particularly in patients with a history of angina or provocable 
myocardial ischemia on stress testing.43 If coronary disease becomes a concern after renal 
transplantation, the intravascular administration of a contrast agent is associated with a high 
risk (>15%) of contrast-induced AKI in the transplanted kidney.44 Thus it is reasonable to 
consider upfront contrast-induced AKI in the native kidneys before transplantation. Kumar 
and co-workers reported on the intermediate-term outcomes of 76 predialysis patients with 
CKD undergoing coronary angiography prior to renal transplantation.45 The mean eGFR 
before contrast exposure was 12.5 ± 3.4 ml/min/1.73 m2 and the mean iodinated contrast 
load administered was 55.7 ± 50.2 ml. In total, 25 of the 76 patients (32.9%) who had 
coronary angiography subsequently underwent transplantation; 22 of the patients who 
underwent transplantation had not received any form of dialysis beforehand. Exposure to 
contrast media did not seem to hasten progression to end-stage renal disease. The 
cumulative dialysis-free survival among all 76 patients who had coronary angiography was 
89.1% at 6 months post coronary angiography. A number of factors probably worked 
together to produce these excellent results and a ‘safe landing’ after coronary angiography. 
Patients were stable and relatively young (mean age 56.3 years). Other factors that 
contributed to favorable outcome include discontinuation of all potentially nephrotoxic 
drugs 24 hours before the angiogram, use of statins, generous hydration prior to procedure, 
use of N-acetylcysteine and iso-osmolar contrast and the use of biplane angiography. 
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Statins have pleiotropic effects and their anti-oxidant properties may play a role against the 
oxidative stress involved in the pathogenesis of contrast induced AKI.46,47 Hydration prior to 
administration of contrast may have multiple theoretical benefits for the kidney which include 
decreased activity of renin angiotensin system, downregulation of tubuloglomerular feedback, 
augmentation of diuresis and sodium excretion, dilution of contrast media, prevention of renal 
cortical vasospasm, reduced pre-constriction of vessels, avoidance of tubular obstruction and 
reduction of endothelin and other renal vasoconstrictors. 48 Reactive oxygen species generated 
by radiocontrast in the renal tubules and peritubular space are believed to be central in the 
pathogenesis of CI-AKI. The potential benefit of N–acetylcysteine has been reported in 
multiple trials including the Acetylcysteine to Prevent Angiography-Related Renal Tissue 
Injury trial.49,50 But the recently completed, large Acetylcysteine for Contrast-Induced 
Nephropathy Trial reported by Berwanger and colleagues has cast a doubt on the effectiveness 
of this agent to prevent this complication. Iodixanol is an iso-osmolar, non ionic dimer used in 
coronary angiography. It is associated with a significantly lower incidence of AKI after 
contrast exposure especially in patients with CKD.51 Finally, biplane angiography is associated 
with a reduction in angiographic contrast volume in patients with CKD. 52, 53 Staging 
complicated intervention can decrease the contrast volume used in a single session and thus 
decrease the risk of AKI provided a sufficient long interim time period is observed (>10 days). 
Kumar and colleagues have demonstrated that the prudent use of intravascular iodinated 
contrast agent and coronary revascularization—with due attention to renal protection—did 
not hasten the progression to end-stage renal disease. Prevention of contrast-induced AKI is 
almost certainly a product of multimodality prophylaxis after careful patient selection and 
pre-, intra-, and post-procedural management.49 Table 1 lists caveats concerning 
nephrotoxic medications and other drugs used in routine management with suggestions to 
possibly reduce adverse events with coronary angiography. 
 
Medications 
Cardiovascular and Renal 
Effects 
Recommendation 
NSAIDs 
Inhibition of production of 
vasodilatory prostaglandins 
leading to vasoconstriction of 
afferent arterioles, increased 
risk of AKI, fluid retention, and 
the development of heart failure
Discontinue at least 3 days prior to 
contrast exposure, switch to narcotics or 
alternative pain treatment 
Antihypertensive 
medications 
*Special mention  
ACE inhibitors 
Reduce the decline in renal 
function 
Can impair tubuloglomerular 
feedback 
Continue 
Consider holding before angiography 
Loop, thiazide, 
and other diuretics
Volume depletion, electrolyte 
abnormalities
Hold day of procedure  
Aminoglycosides 
Interstitial and medullary renal 
injury
Avoid if possible, close monitoring by 
levels if no alternative
Vancomycin  
Enhance nephrotoxic potential 
of other nephrotoxic 
medications, direct 
chemotoxicity 
Continue, closely monitor drug levels 
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Medications 
Cardiovascular and Renal 
Effects 
Recommendation 
Amphotericin B 
Acute renal vasoconstriction 
and distal tubular epithelial 
damage, loss of concentrating 
ability 
Avoid if possible. Intensive monitoring 
of renal function, hydration and acid 
base status if no alternative or switch to 
newer less nephrotoxic agents such as 
caspofungin 
Metformin  
Increased risk of lactic acidosis 
if continued after glomerular 
filtration rate drops 
Hold the day of contrast procedure, and 
generally recommended for another 10 
days 
Statins 
May be protective against 
contrast-induced AKI 
Continue 
Cyclosporine, 
tacrolimus 
Hypertension, dyslipidemia, 
diabetes mellitus, powerful 
inhibitor of CYP450 isozyme 
3A4 and increases levels of 
some statins including 
lovastatin, atorvastatin, and 
simvastatin 
Hold for three days prior to procedure. 
CCB and ACEI preferred choice for 
hypertension. To treat dyslipidemia, 
consider lowering dose, change to 
tacrolimus, diet control and/or lipid-
lowering drugs usually statin with 
preference to pravastatin or rosuvastatin 
therapy. Watch for statin induced 
muscle toxicity/ rhabdomyolysis. Avoid 
toxic levels of cyclosporine and monitor 
blood glucose closely. Initiate early 
therapy for post-transplantation diabetes 
mellitus. 
Sirolimus 
Dyslipidemia, no significant 
impact on hypertension or post-
transplant diabetes mellitus. It 
may interact with drugs 
metabolized by CYP450 
isozyme system. 
Treat dyslipidemia with diet control plus 
lipid-lowering drug therapy usually 
statins with preference to pravastatin or 
rosuvastatin. Consider lowering dose 
and/or change to alternative immune-
suppressant drug if resistant 
dyslipidemia. 
Corticosteroids 
Hypertension, dyslipidemia, 
hyperglycemia, diabetes 
mellitus 
Treat hypertension with CCB, ACEI or 
beta-blockers. Treat dyslipidemia with 
diet control plus lipid-lowering drug 
therapy. Monitor blood sugar levels 
closely and initiate early therapy for post 
transplantation diabetes mellitus. Use of 
lower dosing, if possible. 
Mycophenolate 
mofetil and 
Azathioprine 
Both pose low cardiometabolic 
risks. 
Monitoring for hypertension, diabetes 
mellitus and dyslipidemia when used in 
conjunction with any of the above 
mentioned immunosuppressant drugs. 
Table 1. Common medications and caveats with respect to coronary angiography in renal 
transplant candidates or recipients. 
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5. Coronary revascularization in transplant candidates 
Jones et al divided 250 transplant candidates based on coronary angiography into group 1 
with less than 50% stenosis, group 2 with more than 50% stenosis in 1 vessel, and group 3 
with more than 50% stenosis in 2 or more vessels. Survival was significantly worse in group 
3 when compared to groups 1 and 2. However survival was much better in patients who 
received transplantation in all 3 groups. Therefore severe coronary artery disease should not 
delay or disqualify a CKD patient from receiving renal transplantation.31 Coronary 
intervention in CKD patients is associated with multiple complicated issues that determine 
the outcome. Dialysis patients with coronary stenosis of more than 70% have a higher risk of 
cardiac events and death than patients without coronary artery lesions.14 The Coronary 
Artery Revascularization Prophylaxis (CARP) trial examined the impact of coronary 
revascularization in patients requiring major vascular surgery. Revascularization was not 
associated with any benefit in survival except in patients with left main coronary artery 
disease. Similarly, the American College of Physicians does not recommend prophylactic 
revascularization of asymptomatic patients undergoing noncardiac surgery, stressing the 
fact that asymptomatic low risk pretransplant candidates do not need coronary 
revascularization for renal transplantation.32 Kasiske et al suggested that revascularization 
of significant coronary artery stenosis should occur prior to renal transplantation.13 The 
prolonged survival benefit was confined to left main coronary artery stenosis, left main 
equivalent disease, triple vessel disease with abnormal left ventricular function, and two 
vessel disease with more than 75% stenosis of the left anterior descending artery. 
Revascularization is recommended for left main disease and its equivalents and 
symptomatic patients refractory to medical treatments.33 Manske et al randomized 26 
diabetic pretransplant candidates with significant coronary artery disease into 
revascularization and medical therapy groups prior to renal transplantation. The outcome of 
patients managed medically was significantly inferior to those treated by revascularization. 
Only 2 out of 13 revascularized patients had cardiovascular end points when compared to 
10 out of 13 in the medically managed group.34 Coronary revascularization in renal patients 
is associated with a three fold increase in mortality when compared to patients not requiring 
renal replacement therapy.35 Compared to percutaneous coronary intervention, coronary 
artery bypass grafting is associated with approximately three time greater short term risk of 
postoperative hemodialysis dependence among non-hemodialysis dependent CKD 
patients.36 Similarly, survival rates are significantly lower in dialysis patients at 2 years 
when compared to the general population.35  Percutaneous coronary intervention is shown 
to have a better in hospital and 30 day survival in dialysis patients when compared to 
coronary artery bypass surgery. However coronary artery bypass surgery has better long 
term survival.37 It also appears that there is a higher rate of restenosis of revascularized 
vessels in patients with CKD.38 The use of drug eluting stents may decrease the incidence of 
restenosis, however these stents mandate the use of aspirin and clopidogrel for at least 1 
year as per the present guidelines. Premature discontinuation of an antiplatelet agent is 
associated with significant risk of stent thrombosis. Thus, the combined use of aspirin and 
clopidogrel may delay renal transplantation. For that reason, if coronary intervention is 
contemplated, bare metal stent, balloon angioplasty or bypass grafting should be considered 
if the anatomy is feasible.39 
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6. Angiography in patients after renal transplantation 
Coronary angiography continues to be the gold standard for identifying coronary artery 
disease even in post transplant patients. Renal transplantation does not protect one from the 
adverse effect of contrast on the kidney. Transplant recipients are at high risk of CI-AKI due 
to chronic allograft dysfunction and the high prevalence of diabetes and concomitant use of 
immunosuppressants like cyclosporine and tacrolimus. Agrawal et al found a 15.4% 
incidence of contrast induced nephropathy among post transplant patients undergoing 
coronary angiography. Intravenous hydration, bicarbonate infusion, N-acetylcysteine and 
the use of iso-osmolar contrast agent show varying efficacy in reducing its incidence.44 Thus, 
the renal transplant recipient, appears to be at enhanced risk for CI-AKI compared to 
patients with similar glomerular filtration and bilateral native kidneys. Renal transplant 
recipients should be informed of this increased risk and unnecessary or optional contrast 
exposure should be avoided. 
7. Conclusions 
There are specific cardiovascular benefits to early renal transplantation in CKD patients 
including improved left ventricular function, enhanced overall functional capacity and 
quality of life, and decreased morbidity and mortality. Delay in renal transplantation and 
longer duration of hemodialysis decreases the likelihood of normalization of cardiac systolic 
dysfunction after transplantation. CKD patient with cardiac dysfunction should be 
thoroughly evaluated for underlying ischemia and aggressively treated with anti-anginals, 
angiotensin converting enzyme inhibitors or angiotensin receptor blockers and beta blockers 
before, perioperatively, and after renal transplantation. Every effort must be made to 
promote early renal transplantation when feasible with a living donor.12 An early 
cardiovascular assessment, preferably by cautious coronary angiography utilizing the above 
mentioned renoprotective measures should be performed if indicated, to decrease the 
cardiovascular event rate associated with transplant surgery. A multidisciplinary approach 
involving a cardiologist, an interventionist, a nephrologist, a cardiothoracic and transplant 
surgeon can expedite the process and thus improve post transplant morbidity, mortality, 
functional capacity and overall quality of life.  
8. Abbreviations  
KT = Kidney transplantation,  
CAD = Coronary artery disease,  
CHF = Congestive Heart Failure,  
EKG = Electrocardiogram,  
EF = Ejection Fraction,  
MI = Myocardial infarction,  
DM = Diabetes mellitus,  
AS = Aortic stenosis,  
MR = Mitral regurgitation,  
LDL = Low density lipoprotein,  
PVOD = Peripheral vascular disease,  
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CI-AKI = Contrast induced acute kidney injury,  
NSAIDs = Non steroidal anti-inflammatory drugs,  
AKI  = acute kidney injury,  
CCB = calcium channel blockers,  
ACEI = angiotensin converting enzyme inhibitors,  
eGFR =  estimated glomerular filtration rate,  
MDRD = Modification of Diet in Renal Disease,  
AKI =  Acute Kidney Injury,  
CKD = Chronic Kidney Disease,  
ESRD = End Stage Renal Disease 
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